Du är här

2015-09-23

Actelion Pharmaceuticals Ltd: Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at European Respiratory Society (ERS) Congress 2015

Actelion Pharmaceuticals Ltd / Further data on selexipag (Uptravi) and
macitentan (Opsumit) to be presented atEuropean Respiratory Society (ERS)
Congress 2015 . Processed and transmitted by NASDAQ OMX Corporate
Solutions.The issuer is solely responsible for the content of this
announcement.
ALLSCHWIL, SWITZERLAND - 23 September 2015 -
Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase
III GRIPHON study with the investigational drug selexipag (Uptravi®) will be
shared through an oral presentation at the European Respiratory Society (ERS)
Congress in Amsterdam, Netherlands.

The oral presentation, titled 'Effect of selexipag on long-term outcomes in
key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON
study results' will be given by Professor Olivier Sitbon from the Hospital Le
Kremlin Bicêtre, Paris, France, at 11.15 on 30 September. The abstract can be
found in the congress programonline.

The ERS Congress will also see the presentation of further information on
macitentan (Opsumit®), with a poster titled 'Pharmacokinetics and safety of
concomitant macitentan and hormonal contraceptives'. The poster will be
presented in a poster discussion session by Dr Noémie Hurst from 10.45 on 28
September. The abstract can be found in the congress programonline.

###

Notes to Editor:

SELEXIPAG AT ERS-15

Oral presentation:
Effect of s
elexipag on long-term outcomes in key subgroups of patients with pulmonary
arterial hypertension (PAH): GRIPHON study results

O. Sitbon,R. Channick, K. Chin, A. Frey, N. Galiè, H.-A. Ghofrani, M.M.
Hoeper, I. Lang, F.-O. Le Brun, V. McLaughlin, R. Preiss, L.J. Rubin, G.
Simonneau, V. Tapson, S. Gaine
Wednesday, September 30, 11:15 - 11:30, Room 4.1

MACITENTAN AT ERS-15

Poster presentation:

Pharmacokinetics and safety of concomitant macitentan and hormonal
contraceptives

N. Hurst. M. Pellek, P.N. Sidharta, J. Dingemanse

Monday, September 28, 10:45 - 12:45, Room E102

ACTELION LTD

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
Our portfolio of PAH treatments covers the spectrum of disease, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications. Although not available in all countries, Actelion has treatments
approved by health authorities for a number of specialist diseases including
Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in
patients suffering from systemic sclerosis, and mycosis fungoides type
cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including Europe, the US, Japan, China, Russia
and Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All
trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations&Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "are expected to", "will", "will continue", "should", "would be",
"seeks", "pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of
the company's investment and research and development programs and
anticipated expenditures in connection therewith, descriptions of new
products expected to be introduced by the company and anticipated customer
demand for such products and products in the company's existing portfolio.
Such statements reflect the current views of the company with respect to
future events and are subject to certain risks, uncertainties and
assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future
results, performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those described herein as
anticipated, believed, estimated or expected.

Press Release PDF
http://hugin.info/131801/R/1953700/710950.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire

HUG#1953700

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.